Why Rezolute, Inc.’s (RZLT) Stock Is Down 5.77%
As of Friday, October 16, Rezolute, Inc.’s RZLT share price has dipped by 5.77%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Rezolute, Inc.’s (RZLT) Stock Is Down 5.86%
As of Wednesday, October 14, Rezolute, Inc.’s RZLT share price has dipped by 5.86%, which has investors questioning if this is right time to buy.Michael Rose
Why Rezolute, Inc.’s (RZLT) Stock Is Up 5.06%
As of Friday, October 09, Rezolute, Inc.’s RZLT share price has surged by 5.06%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Rezolute, Inc.’s (RZLT) Stock Is Up 5.38%
As of Wednesday, September 30, Rezolute, Inc.’s RZLT share price has surged by 5.38%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Rezolute, Inc.’s (RZLT) Stock Is Down 5.70%
As of Friday, September 18, Rezolute, Inc.’s RZLT share price has dipped by 5.70%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | RZLT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $388.1 | $228.4 | 35% |
|
| Shares Out (Mil) | 104.5 | 53.9 | 63% |
|
| Institutional Ownership | 98.7% | 92.9% | 81% |
|
| Float (Mil) | 65.9 | 41.7 | 53% |
|
| Beta | 0.61 | 0.95 | 36% |
|
| Avg Daily Volume (000s) | 1,649 | 582 | 78% |
|
| Price Change (52-week) |
(57.4%) | 47.6% | 16% |
|
| Growth | RZLT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (30.0%) | (10.1%) | 14% |
|
| EPS (5yr) | 22.8% | 15.8% | 72 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (17.1%) | (15.7%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 7 | |
| Current EPS | ($0.185) | ($0.698) | ($0.469) | |
| Month Ago EPS | ($0.146) | ($0.626) | ($0.280) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | ($0.146) | ($0.626) | ($0.280) | |
| Year/Year Chg | (5.6%) | (6.6%) | (45.9%) | |
| Financials | RZLT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($78) | ($44) | 13% |
|
| EPS (TTM) | ($0.747) | ($1.500) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($65) | ($33) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($84) | $2 | 16% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 13% |
|
| Enterprise Value (Q1) (Mil) | $320 | $177 | 30% |
|
| Valuation | RZLT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.56 | 2.19 | 72% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RZLT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (53.8%) | (47.1%) | 11% |
|
| ROE | (59.0%) | (54.1%) | 14% |
|
| Liabilities to Assets | 10.8% | 29.1% | 6% |
|
| F-Score | 2 | 2 | 7% |
|
Rezolute, Inc. did not pass any screens on 10/20/2026.
